Advanced Oncotherapy (AVO)
AVO Share PerformanceMore
|52 week high||91.850 09/01/17|
|52 week low||9.525 19/07/17|
|52 week change||-2.250 (-4.50%)|
|4 week volume||9,427,018 20/11/17|
Media for (AVO)
Presenter: Nicolas Serandour
Presenter: AVO Team
- 1 of 16
Latest News« previous» nextMore
13/12/2017 - 16:25 RNS
RNS Number: 2803Z Advanced Oncotherapy PLC 13 December 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Advanced Oncotherapy Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of votin...
11/12/2017 - 14:02 RNS
RNS Number: 9872Y Advanced Oncotherapy PLC 11 December 2017 Hardman Research: Distribution agreement and capital increase Distribution agreement and capital increase: AVO is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world-renowned CERN. Major milestones have be...
11/12/2017 - 00:00 BRR Media
07/12/2017 - 09:32 StockMarketWire
Advanced Oncotherapy has signed an exclusive distribution agreement to market and sell its LIGHT system across China, ...
07/12/2017 - 07:00 RNS
RNS Number: 6613Y Advanced Oncotherapy PLC 07 December 2017 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Exclusive distribution agreement for China and other geographies & new equity investments for a total consideration of 37 million Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton th...
22/10/2017 - 23:00 BRR Media
29/09/2017 - 06:37 StockMarketWire
Advanced Oncotherapy's operating losses rose to 7.3m in the six months to the end of June - up from 5.9m last time. Revenu...
29/09/2017 - 06:00 RNS
RNS Number: 1735S Advanced Oncotherapy PLC 29 September 2017 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Half-year Report Advanced Oncotherapy (AIM: AVO), the developer of a next generation proton therapy system for cancer treatment, announces its unaudited results for the six months ended 30 June 2017 and po...
|Dividend yield||0 %|
Latest discussion posts More
“So there it is Great deal, by the looks of it. Fully financed for the long term, all looking on track. Directors buying more, and a partner to sell to the far east. Not ...”▼
“Nice tick up today on smallish volume, hopefully means good news coming.”▼
“Wow that's more than enough to cover the next few years and take them past live for Harley Street. I suppose it depends on how much they have to give away in equity, their ...”▼
Codes & Symbols
|Symbols||AVO, LSE:AVO, AVO.L, AVO:LN, LON:AVO, XLON:AVO|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment